Abstract 5696: Discovery of putative breast cancer antigens using genomics-driven immunoproteomics

Abstract

Abstract Recent advances in cancer immunotherapeutics such as checkpoint inhibitors, chimeric antigen-receptor T cells, and tumor-infiltrating T cells (TIL) are now significantly impacting cancer patients in a positive manner. Although very promising, reports indicate no more than 25% of cases result in complete remission. One of the limitations of these treatments is the identity of cancer antigens in each patient as it is technically challenging to identify cancer antigens in a rapid fashion. Thus, identification of cancer antigens for each patient followed by targeted treatment will likely increase the efficacy of cancer immunotherapies. To achieve this goal, a combined technologies of deep genomic sequencing and personalized immune assessment platform was devised, termed Genomics-Driven Immunoproteomics (GDI). Using this technological platform, we report the discovery of 149 putative tumor antigens from human breast cancer patients. Significant numbers of these cancer antigens arise from single nucleotide variants (SNVs), as well as insertions and deletions that results into frame-shift mutations. We propose a general model of anticancer immunity and suggest that GDI platform may help identify patient-specific tumor antigens in a timely fashion for precision immunotherapies. Citation Format: David K. Han. Discovery of putative breast cancer antigens using genomics-driven immunoproteomics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5696.